References — Disease2Target Pancreatic KRAS-Combination Validation

index | discussion

---

1. Chen JY, et al. Drug Discovery at the Speed of AI (presentation), slides 25–40 and 67. SPARC, UAB.

2. Chen JY, Saghapour E, Kurmachalam N, Oishe G, Sembay Z. Induced ERBB response and standing FAK dependency nominate separable KRAS-combination hypotheses in pancreatic cancer. Zenodo 2026. doi:10.5281/zenodo.21290630 Code and data: https://github.com/aimed-lab/kras-combo-therapy

3. Zhang A, Chen JY. Intelligent Oncology 2025;1(3):233–243.

4. Disease2Target source code. https://github.com/aimed-lab/DiseaseToGene (commit 6fcd205).

5. Dempster JM, et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol 2021;22:343.

6. Abstract 6497: Synergistic disruption of KRAS and FAK pathways: a preclinical pipeline for PDAC therapy optimization. Cancer Res 2026;86(7_Suppl):6497.

7. RASolute 302: daraxonrasib vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma. ClinicalTrials.gov NCT06625320.

Also cited in the co-pilot check

• RASolute (second Phase 3 trial): ClinicalTrials.gov NCT07491445.
• Disease2Target app: https://target.smartdrugdiscovery.org/